Over the past several decades,there have been major advancements in the field of glucose sensing and insulin delivery for the treatment of type I diabetes mellitus.The introduction of closed-loop insulin delivery syst...Over the past several decades,there have been major advancements in the field of glucose sensing and insulin delivery for the treatment of type I diabetes mellitus.The introduction of closed-loop insulin delivery systems that deliver insulin in response to specific levels of glucose in the blood has shifted significantly the research in this field.These systems consist of encapsulated glucose-sensitive components such as glucose oxidase or phenylboronic acid in hydrogels,microgels or nanoparticles.Since our previous evaluation of these systems in a contribution in 2004,new systems have been developed.Important improvements in key issues,such as consistent insulin delivery over an extended period of time have been addressed.In this contribution,we discuss recent advancements over the last 5 years and present persisting issues in these technologies that must be overcome in order for these systems to be applicable in patients.展开更多
基金supported in part by the Dean of the Cockrell School of Engineering at The University of Texas at Austin for the Institute for Biomaterials,Drug Delivery and Regenerative Medicinethe UT-Portugal Collaborative Research Program.
文摘Over the past several decades,there have been major advancements in the field of glucose sensing and insulin delivery for the treatment of type I diabetes mellitus.The introduction of closed-loop insulin delivery systems that deliver insulin in response to specific levels of glucose in the blood has shifted significantly the research in this field.These systems consist of encapsulated glucose-sensitive components such as glucose oxidase or phenylboronic acid in hydrogels,microgels or nanoparticles.Since our previous evaluation of these systems in a contribution in 2004,new systems have been developed.Important improvements in key issues,such as consistent insulin delivery over an extended period of time have been addressed.In this contribution,we discuss recent advancements over the last 5 years and present persisting issues in these technologies that must be overcome in order for these systems to be applicable in patients.
